新辅助化疗在初始可切除结直肠癌肝转移中的研究进展

肝癌电子杂志 ›› 2019, Vol. 6 ›› Issue (4): 24-26.

新辅助化疗在初始可切除结直肠癌肝转移中的研究进展

陈启晨, 周健国*()

国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科, 北京 100021

出版日期:2019-12-30 发布日期:2020-01-19
通讯作者: 周健国 E-mail:zjgty@hotmail.com
作者简介:陈启晨在读硕士研究生,中国医学科学院肿瘤医院,肝胆外科
基金资助:
中国传染病国家重点项目(2017ZX10201021-007-003);首都卫生发展科研专项项目(2018-1-4021);国家自然科学基金(81672461);国家自然科学基金(81972311);中国医学科学院医学与健康科技创新工程(2016-I2M-1-001);中国医学科学院医学与健康科技创新工程(2017-12M-4-002)

Online:2019-12-30 Published:2020-01-19

摘要/Abstract

摘要：

结直肠癌是全球常见的恶性肿瘤之一,肝脏是结直肠癌最常见的转移器官。肝转移的治疗已成为改善结直肠癌患者预后的重要因素。手术是结直肠癌肝转移首选的治疗手段,术前新辅助化疗的应用有助于降低原发肿瘤局部分期及减少肝转移灶的瘤体负荷,提高手术切除率,进而使得患者的生存获益。对于初始可切除的结直肠癌肝转移患者行新辅助化疗,是目前临床研究的热点之一。因此本文就获益人群的选择、联合靶向药物的使用、疗效评估及手术时机的选择等几个方面对初始可切除的结直肠癌肝转移行新辅助化疗的研究进展进行综述。

陈启晨, 周健国. 新辅助化疗在初始可切除结直肠癌肝转移中的研究进展[J]. 肝癌电子杂志, 2019, 6(4): 24-26.

参考文献 33

[1]	Torre LA, Bray F, Siegel RL , et al. Global cancer statistics, 2012[J]. CA: a cancer journal for clinicians, 2015,65(2):87-108.
[2]	Engstrand J, Nilsson H, Strömberg C , et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival[J]. BMC cancer, 2018,18(1):78.
[3]	葛大壮, 赵建军, 黄振, 毕新宇, 蔡建强 . MDT指导下多程治疗直肠癌肝转移临床治愈一例[J]. 肝癌电子杂志, 2019,6(03):24-27.
[4]	B Section of Gastrointestinal Surgery CMA, B Section of Colorectal & Anal Surgery, Chinese Medical Association; A CoCCoCA-C;, CCoS Chinese Society of Colon & Rectal Surgeons, Chinese Medical Doctors Association;, CIEaPAfMaHC Committee of Colorectal Liver Metastases Treatment.: Guideline for the diagnosis and comprehensive treatment of colorectal cancer with liver metastases (2016 edition). Chin J Dig Surg, 2016: 15(18):755-767.
[5]	ONCOLOGY CSOC. GUIDELINES OF CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) COLORECTAL CANCER[J]. People's Medical Publishing House, 2019.
[6]	Network NCC . NCCN clinical practice guidelines in Oncology:Rectal Cancer(2019.V2)[J]. 2019.
[7]	Beppu T, Miyamoto Y, Sakamoto Y, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival[J]. Annals of surgical oncology, 2014,21 Suppl 3: S405-413.
[8]	Hubert C, Lucidi V, Weerts J , et al. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases[J]. European journal of surgical oncology, 2018,44(10):1532-1538.
[9]	Vigano L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival[J]. Annals of surgery, 2013, 258(5): 731-740; discussion 741-732.
[10]	Zhao J, van Mierlo KMC, Gomez-Ramirez J , et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases[J]. The British journal of surgery, 2017,104(8):990-1002.
[11]	Adam R, Bhangui P, Poston G , et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases[J] ? Annals of surgery, 2010,252(5):774-787.
[12]	Konopke R, Kersting S, Distler M , et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases[J]. Liver international, 2009,29(1):89-102.
[13]	Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation[J]. Archives of surgery, 2007, 142(3): 269-276; discussion 277.
[14]	Nagashima I, Takada T, Matsuda K , et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection[J]. Journal of hepato-biliary-pancreatic surgery, 2004,11(2):79-83.
[15]	Fong Y, Fortner J, Sun RL , et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Annals of surgery, 1999, 230(3): 309-318; discussion 318-321.
[16]	Ayez N, van der Stok EP, Grunhagen DJ , et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator[J]. European journal of surgical oncology, 2015,41(7):859-867.
[17]	Zhu D, Zhong Y, Wei Y , et al. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases[J]. PloS one, 2014,9(1):e86543.
[18]	Liu W, Zhou JG, Sun Y , et al. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis[J]. Oncotarget, 2016,7(24):37277-37287.
[19]	Van Cutsem E, Cervantes A, Adam R , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Annals of oncology, 2016,27(8):1386-1422.
[20]	Sabanathan D, Eslick GD, Shannon J . et al. Use of Neoadjuvant Chemotherapy Plus Molecular Targeted Therapy in Colorectal Liver Metastases: A Systematic Review and Meta-analysis[J]. Clinical colorectal cancer, 2016,15(4):e141-e147.
[21]	Primrose J, Falk S, Finch-Jones M , et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial[J]. The Lancet Oncology, 2014,15(6):601-611.
[22]	Hurwitz H, Fehrenbacher L, Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. The New England journal of medicine, 2004,350(23):2335-2342.
[23]	Lim C, Doussot A, Osseis M , et al. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first[J]. Clinical & translational oncology, 2018,20(10):1274-1279.
[24]	Rong Z, Martel G, Vandenbroucke-Menu F , et al. Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey[J]. HPB, 2014,16(4):342-349.
[25]	Ranpura V, Hapani S, Wu S , et al. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis[J]. JAMA, 2011,305(5):487-494.
[26]	Rubbia-Brandt L, Giostra E, Brezault C , et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery[J]. Annals of oncology, 2007,18(2):299-304.
[27]	Serayssol C, Maulat C, Breibach F , et al. Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy[J]. World journal of gastrointestinal oncology, 2019,11(4):295-309.
[28]	Blazer DG, Kishi Y, Maru DM , et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases[J]. Journal of clinical oncology, 2008,26(33):5344-5351.
[29]	Mao R, Zhao JJ, Bi XY , et al. A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases[J]. Journal of gastrointestinal surgery, 2019,23(3):563-570.
[30]	Shaikh T, Ruth K, Scott WJ , et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer[J]. The Annals of thoracic surgery, 2015,99(1):270-276.
[31]	Ruol A, Rizzetto C, Castoro C , et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? [J] Annals of surgery, 2010,252(5):788-796.
[32]	Liu Y, Zhang KC, Huang XH , et al. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes[J]. World Journal of gastroenterology, 2018,24(2):257-265.
[33]	Lin G, Han SY, Xu YP , et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies[J]. Diseases of the esophagus, 2016,29(8):1107-1114.

新辅助化疗在初始可切除结直肠癌肝转移中的研究进展

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 1

编辑推荐

Metrics

本文评价